SCHEMBL64306

SCHEMBL64306

CC12CCC(NC(=O)OCc3ccccc3)(CC1)c1nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n1C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
CYP2C9 P11712 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
ERCC1 P07992 1/20 0.36
FEN1 P39748 1/20 0.36
ERCC4 Q92889 1/20 0.36
CNR2 P34972 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
CALCA P06881 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62281 0.86 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL62481 0.83 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL63048 0.83 HPGD (0.36) CYP2C9SMN1; SMN2L3MBTL1LMNAMAPT
SCHEMBL63394 0.83 KCNH2 (0.40) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL63101 0.83 KCNH2 (0.43) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL62449 0.83 CYP2C9 (0.52) KCNH2CYP2C9SMN1; SMN2L3MBTL1MAPT
SCHEMBL62526 0.82 KCNH2 (0.49) KCNH2CYP2C9SMN1; SMN2L3MBTL1MAPT
SCHEMBL63287 0.81 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA
SCHEMBL9942973 0.81 MMP13 (0.35) KCNH2CYP2C9
SCHEMBL63543 0.81 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885SMN1; SMN2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.